MedTrace Logo

PK,PD and DDI of Epaminurad and Naproxen in Healthy Volunteers

NCT06435442 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2026-04-16

No results posted yet for this study

Summary

A Phase 1 Study to evaluate the safety, PK/PD, drug-drug interaction(DDI) of Epaminurad and Naproxen in Healthy Volunteers

Conditions

  • Healthy

Interventions

DRUG

Epaminurad, Naproxen

Period 1: Epaminurad 6mg -\> Epaminurad 9mg -\> Epaminurad 9mg +Naproxen Period 2: Naproxen

DRUG

Epaminurad

Epaminurad

DRUG

Epaminurad placebo

Epaminurad placebo

Sponsors & Collaborators

Principal Investigators

  • Kyung-sang Yu, MD · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-03
Primary Completion
2025-12-30
Completion
2025-12-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06435442 on ClinicalTrials.gov